by DealForma Analysts | Aug 1, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer Top Biopharma Partnership by Upfront Cash and Equity July 2021 Arvinas development and commercialization deal with Pfizer for ARV-471...
by DealForma Analysts | Jul 1, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal June 2021: iTeos – GSK for EOS-448 anti-TIGIT mAb for Solid Tumors Top Biopharma Partnership by Upfront Cash and Equity June 2021 iTeos development and commercialization deal with GSK for EOS-448 Announced: June 14, 2021...
by DealForma Analysts | Jun 5, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal May 2021: Agenus – BMS for AGEN-1777 Bispecific Anti-TIGIT Antibody for Non-Small Cell Lung Cancer Top Biopharma Partnership by Upfront Cash and Equity May 2021 Agenus development and commercialization deal with BMS for AGEN-1777...
by DealForma Analysts | Apr 30, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia Top Biopharma Partnership by Upfront Cash and Equity April 2021 CRISPR Therapeutics amending its development and...
by DealForma Analysts | Apr 12, 2021 | Deal of the Month
Deal of the Month Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer Top Biopharma Partnership by Upfront Cash and Equity March 2021 Debiopharm development and commercialization deal with Merck KGaA for Xevinapant...
by DealForma Analysts | Mar 10, 2021 | Deal of the Month
Deal of the Month Biopharma Deal of the Month: Vir – GSK for VIR-2482 and mAbs for Influenza Top Biopharma Partnership by Upfront Cash and Equity February 2021 VIR and GSK Expanding VIR-2482 and mAb Development into Influenza Announced: Feb. 17, 2021 Total Deal...
by DealForma Analysts | Jun 20, 2019 | Analysis, Funding, M&A, Partnership Deals
Analysis | Funding | M&A | Partnership Deals Gene Therapy Deals, M&A, and Venture Funding Gene therapy deals, R&D partnerships, and acquisitions have been showing annual gains through 2018 and are on track to keep up the record in 2019. The recent...
by DealForma Analysts | Jun 13, 2019 | Analysis, M&A
Analysis | M&A Reverse Mergers in Biopharma Reverse mergers have been a relatively quick method for companies to gain a public listing as an alternative to IPOs. A private company looking to go public merges with a company that is already publicly traded and...
by DealForma Analysts | Jan 22, 2019 | Analysis, Funding
Analysis | Funding Top 10 Venture Round Investors in Cancer Therapeutics Celgene’s recent acquisition offer by Bristol-Myers Squibb has raised attention to its prolific dealmaking history. We covered this in a recent article in Endpoints News. Celgene was also...
by DealForma Analysts | Sep 4, 2018 | Analysis, Partnership Deals
Analysis | Partnership Deals Top 10 Biopharma Dealmakers by Upfront Cash Data from the DealForma database and an analysis were prepared for a story published in Endpoints News looking at top dealmakers in recent biopharma partnerships. We applied certain criteria to...
